Maria Pernemalm

About me

The analysis of human blood plasma with modern -omics technologies holds an enormous potential to reveal biomarkers for diagnosis and treatment selection, as well as studying complex systemic signalling events that are involved in immune modulation, metastatic spread and disease progression. 

My primary research interest is exploring how events on tissue and cellular level are reflected on the molecular level in human blood plasma and how these can be monitored using -omics methods. I have a long-standing interest and expertise in method development for mass spectrometry (MS) based plasma proteomics and in combining different analytical approaches and data sources with the aim to improve the understanding of the dynamics in the plasma proteome, in particularly related to biomarker discovery in lung cancer and malignant melanoma. 

The plasma team works both on method development and applied projects involving expanded applications of plasma proteome analysis such as plasma protein interaction with viruses and nanoparticles, proteogenomics biomarker discovery, and approaches to combine biochemical plasma markers with symptoms clusters for improved accuracy and sensitivity in precision medicine.

Education

2022 Associate professor in Medical Proteomics, KI, Dept. Oncology Pathology

2009 PhD KI, Dept. Oncology Pathology

2010-2011 KI, Dept. Oncology Pathology, Post Doc 

2011-2012 Scilifelab/KI/Dept. Oncology Pathology, Post Doc 

2012-2013 The University of Manchester, Stem cell & leukemia proteomics lab, Post Doc 

2013-2014 Scilifelab/KI/Dept. Oncology Pathology, Post Doc

2014- Scilifelab/KI/Dept. Oncology Pathology, Assistant professor